RT Journal Article
SR Electronic
T1 An atlas of associations between polygenic risk scores from across the human phenome and circulating metabolic biomarkers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.14.21265005
DO 10.1101/2021.10.14.21265005
A1 Si Fang
A1 Michael V Holmes
A1 Tom R Gaunt
A1 George Davey Smith
A1 Tom G Richardson
YR 2021
UL http://medrxiv.org/content/early/2021/10/25/2021.10.14.21265005.abstract
AB Polygenic risk scores (PRS) are becoming an increasingly popular approach to predict complex disease risk, although they also hold the potential to develop insight into the molecular profiles of patients with an elevated genetic predisposition to disease. In this study, we have constructed an atlas of associations between 129 different PRS and 249 circulating metabolites in up to 83,004 participants from the UK Biobank study. As an exemplar to demonstrate the value of this atlas we conducted a hypothesis-free evaluation of all associations with glycoprotein acetyls (GlycA), an inflammatory biomarker. Using bi-directional Mendelian randomization, we find that the associations highlighted likely reflect the effect of risk factors, such as body mass index (Beta=0.16 per standard deviation change in GlycA, 95% CI=0.11 to 0.21, P=9.9×10−10) or liability towards smoking cigarettes (Beta=0.28, 95% CI=0.20 to 0.35, P=2.4×10−14), on systemic inflammation as opposed to the converse direction of effect. Furthermore, we repeated all analyses in our atlas within age strata to investigate potential sources of collider bias, such as medication usage. This was exemplified by comparing associations between lipoprotein lipid profiles and the coronary artery disease PRS in the youngest and oldest age strata, which had differing proportions of individuals undergoing statin therapy. All results can be visualised at http://mrcieu.mrsoftware.org/metabolites_PRS_atlas.Competing Interest StatementTGR is employed part-time by Novo Nordisk outside of this work. MVH has consulted for Boehringer Ingelheim, and in adherence to the University of Oxford's Clinical Trial Service Unit & Epidemiological Studies Unit (CSTU) staff policy, did not accept personal honoraria or other payments from pharmaceutical companies. TRG receives funding from Biogen for unrelated research. All other co-authors declare no conflict of interest.Funding StatementAll authors work at the MRC Integrative Epidemiology Unit at the University of Bristol (MC_UU_00011/1, MC_UU_00011/4). TRG and GDS conduct research at the NIHR Biomedical Research Centre at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. This work was supported by the British Heart Foundation (AA/18/7/34219). SF is supported by a Wellcome Trust PhD studentship in Molecular, Genetic and Lifecourse Epidemiology [108902/Z/15/Z]. MVH works in a unit that receives funding from the UK Medical Research Council and is supported by a British Heart Foundation Intermediate Clinical Research Fellowship (FS/18/23/33512) and the National Institute for Health Research Oxford Biomedical Research Centre.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Our work involves the previously collected genetic sequencing and metabolites data of human participants in the UK Biobank cohort study. The North West Multi-centre Research Ethics Committee (MREC) gave ethical approval for the UK Biobank.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are either contained in the manuscript or available online at http://mrcieu.mrsoftware.org/metabolites_PRS_atlas/. http://mrcieu.mrsoftware.org/metabolites_PRS_atlas/